• 1
    Yui Y, Sumiyoshi T, Kodama K, et al.Comparison of nifedipine retard with angiotensin converting enzyme inhibitors in Japanese hypertensive patients with coronary artery disease: the Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) randomized trial. Hypertens Res.2004;27:181191.
  • 2
    Yui Y, Sumiyoshi T, Kodama K, et al.Nifedipine retard was as effective as angiotensin converting enzyme inhibitors in preventing cardiac events in high-risk hypertensive patients with diabetes and coronary artery disease: the Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) subgroup analysis. Hypertens Res.2004;27:449456.
  • 3
    Shinoda E, Yui Y, Kodama K, et al.Quantitative coronary angiogram analysis. Nifedipine retard versus angiotensin-converting enzyme inhibitors (JMIC-B side arm study). Hypertension.2005;45:11531158.
  • 4
    Yui Y, Shinoda E, Kodama K, et al.Nifedipine retard prevents hospitalization for angina pectoris better than angiotensin-converting enzyme inhibitors in hypertensive japanese patients with previous myocardial infarction (JMIC-B substudy). J Hypertens.2007;25:20192026.
  • 5
    Yui Y, Kodama K, Hirayama A, et al.Reverse remodeling and improved function by antihypertensive treatment in hypertensive patients with coronary artery disease. J Hypertens.2010;28:178185.
  • 6
    Go AS, Chertow GM, Fan D, et al.Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med.2004;351:12961305.
  • 7
    Solomon SD, Rice MM, A Jablonski K, et al.Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial. Circulation.2006;114:2631.
  • 8
    Anavekar NS, McMurray JJ, Velazquez EJ, et al.Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med.2004;351:12851295.
  • 9
    Levy AS, Coresh J, Greene T, et al.Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med.2006;145:247254.
  • 10
    Moe S, Druke T, Cunningham J, et al.Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int.2006;69:19451953.
  • 11
    Shepherd J, Kastelein John JP, Bittner V, et al.Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to new Targets (TNT) Study. Clin J Am Soc Nephrol.2007;2:11311139.
  • 12
    Colhoun HM, Betteridge DJ, Durrington PN, et al.Effects of atorvastatin on kidney outcomes and cardiovascular diseases in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS). Am J Kidney Dis.2009;54:810819.
  • 13
    Palmer BF. Renal dysfunction complicating the treatment of hypertension. N Engl J Med.2002;347:12561261.
  • 14
    Lewis EJ, Hunsicker LG, Clarke WR, et al.Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med.2001;345:851860.
  • 15
    Brenner BM, Cooper ME, de Zeeuw D, et al.Effects of losaltan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med.2001;345:861869.
  • 16
    Baba S; J-MIND Study Group. Nifedipine and enalapril equally reduce the progression of nephropathy in hypertensive type 2 diabetics. Diabetes Res Clin Pract.2001;54:191201.
  • 17
    Pettinger WA, Lee HC, Reisch J, Mitchell HC. Long-term improvement in renal function after short-term strict blood pressure control in hypertensive nephrosclerosis. Hypertension.1989;13:766772.
  • 18
    Hu B, Gadegbeku C, Lipkowitz MS, et al.Kidney function can improve in patients with hypertensive CKD. J Am Soc Nephrol.2012;23:706713.